• 1
    Chen A, Yahalom D, Ben-Aroya N, Kaganovsky E, Okon E & Koch Y (1998) A second isoform of gonadotropin-releasing hormone is present in the brain of human and rodents. FEBS Lett 435, 199203.
  • 2
    White RB, Eisen JA, Kasten TL & Fernald RD (1998) Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci USA 95, 305309.
  • 3
    Densmore VS & Urbanski HF (2003) Relative effect of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on gonadotropin release. J Clin Endocrinol Metab 88, 21262134.
  • 4
    Kauffman AS (2004) Emerging functions of gonadotropin-releasing hormone II in mammalian physiology and behaviour. J Neuroendocrinol 16, 794806.
  • 5
    Schally AV, Comaru-Schally AM & Redding TW (1984) Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med 175, 259281.
  • 6
    Peng C, Fan NC, Ligier M, Vaananen J & Leung PC (1994) Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells. Endocrinology 135, 17401746.
  • 7
    Brus L, Lambalk CB, de Koning J, Helder MN, Janssens RM & Schoemaker J (1997) Specific gonadotrophin-releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles. Hum Reprod 12, 769773.
  • 8
    Choi JH, Gilks CB, Auersperg N & Leung PC (2006) Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. J Clin Endocrinol Metab 91, 45624570.
  • 9
    Choi KC, Auersperg N & Leung PC (2001) Expression and antiproliferative effect of a second form of gonadotropin-releasing hormone in normal and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 86, 50755078.
  • 10
    Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F & Knuppen R (1989) Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 25, 215221.
  • 11
    Chien CH, Chen CH, Lee CY, Chang TC, Chen RJ & Chow SN (2004) Detection of gonadotropin-releasing hormone receptor and its mRNA in primary human epithelial ovarian cancers. Int J Gynecol Cancer 14, 451458.
  • 12
    Cheung LW, Leung PC & Wong AS (2006) Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res 66, 1090210910.
  • 13
    Chen CL, Cheung LW, Lau MT, Choi JH, Auersperg N, Wang HS, Wong AS & Leung PC (2007) Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. Endocrine 31, 311320.
  • 14
    Srkalovic G, Wittliff JL & Schally AV (1990) Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 50, 18411846.
  • 15
    Chatzaki E, Bax CM, Eidne KA, Anderson L, Grudzinskas JG & Gallagher CJ (1996) The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor. Cancer Res 56, 20592065.
  • 16
    Imai A, Ohno T, Iida K, Fuseya T, Furui T & Tamaya T (1994) Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol Oncol 55, 144148.
  • 17
    Marinaccio M, Reshkin S, Pinto V & Paradiso A (1994) The estimation of LHRH receptors in the tissue of human leiomyoma, myometrium and endometrium. Minerva Ginecol 46, 519526.
  • 18
    Iwashita M, Evans MI & Catt KJ (1986) Characterization of a gonadotropin-releasing hormone receptor site in term placenta and chorionic villi. J Clin Endocrinol Metab 62, 127133.
  • 19
    Casan EM, Raga F & Polan ML (1999) GnRH mRNA and protein expression in human preimplantation embryos. Mol Hum Reprod 5, 234239.
  • 20
    Boyle TA, Belt-Davis DI & Duello TM (1998) Nucleotide sequence analyses predict that human pituitary and human placental gonadotropin-releasing hormone receptors have identical primary structures. Endocrine 9, 281287.
  • 21
    Lin LS, Roberts VJ & Yen SS (1995) Expression of human gonadotropin-releasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion. J Clin Endocrinol Metab 80, 580585.
  • 22
    Kottler ML, Starzec A, Carre MC, Lagarde JP, Martin A & Counis R (1997) The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer. Int J Cancer 71, 595599.
  • 23
    Moriya T, Suzuki T, Pilichowska M, Ariga N, Kimura N, Ouchi N, Nagura H & Sasano H (2001) Immunohistochemical expression of gonadotropin releasing hormone receptor in human breast carcinoma. Pathol Int 51, 333337.
  • 24
    Eidne KA, Flanagan CA, Harris NS & Millar RP (1987) Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64, 425432.
  • 25
    Eidne KA, Flanagan CA & Millar RP (1985) Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 229, 989991.
  • 26
    Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M & Motta M (1999) The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 140, 52505256.
  • 27
    Tieva A, Stattin P, Wikstrom P, Bergh A & Damber JE (2001) Gonadotropin-releasing hormone receptor expression in the human prostate. Prostate 47, 276284.
  • 28
    Straub B, Muller M, Krause H, Schrader M, Goessl C, Heicappell R & Miller K (2001) Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers. Clin Cancer Res 7, 23402343.
  • 29
    Kakar SS, Grizzle WE & Neill JD (1994) The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol 106, 145149.
  • 30
    Emons G, Schroder B, Ortmann O, Westphalen S, Schulz KD & Schally AV (1993) High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 77, 14581464.
  • 31
    Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Holzel F, Schulz KD & Schally AV (1993) High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53, 54395446.
  • 32
    Segal-Abramson T, Kitroser H, Levy J, Schally AV & Sharoni Y (1992) Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc Natl Acad Sci USA 89, 23362339.
  • 33
    Qayum A, Gullick W, Clayton RC, Sikora K & Waxman J (1990) The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 62, 9699.
  • 34
    Pahwa GS, Kullander S, Vollmer G, Oberheuser F, Knuppen R & Emons G (1991) Specific low affinity binding sites for gonadotropin-releasing hormone in human endometrial carcinomata. Eur J Obstet Gynecol Reprod Biol 41, 135142.
  • 35
    Thompson MA, Adelson MD & Kaufman LM (1991) Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium. J Clin Endocrinol Metab 72, 10361041.
  • 36
    Volker P, Grundker C, Schmidt O, Schulz KD & Emons G (2002) Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 186, 171179.
  • 37
    Connor JP, Buller RE & Conn PM (1994) Effects of GnRH analogs on six ovarian cancer cell lines in culture. Gynecol Oncol 54, 8086.
  • 38
    Slotman BJ, Poels LG & Rao BR (1989) A direct LHRH-agonist action on cancer cells is unlikely to be the cause of response to LHRH-agonist treatment. Anticancer Res 9, 7780.
  • 39
    Arencibia JM & Schally AV (2000) Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line. Int J Oncol 16, 10091013.
  • 40
    Gunthert AR, Grundker C, Bottcher B & Emons G (2004) Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells. Anticancer Res 24, 17271732.
  • 41
    Grundker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B & Emons G (2004) Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 151, 141149.
  • 42
    Grundker C, Gunthert AR, Millar RP & Emons G (2002) Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 87, 14271430.
  • 43
    Kim KY, Choi KC, Auersperg N & Leung PC (2006) Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr Relat Cancer 13, 211220.
  • 44
    Yano T, Pinski J, Radulovic S & Schally AV (1994) Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 91, 17011705.
  • 45
    Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K & Schally AV (1994) Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA 91, 70907094.
  • 46
    Schally AV (1999) Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 20, 12471262.
  • 47
    Imai A, Takagi A, Horibe S, Takagi H & Tamaya T (1998) Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. Int J Oncol 13, 97100.
  • 48
    Kleinman D, Douvdevani A, Schally AV, Levy J & Sharoni Y (1994) Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis. Am J Obstet Gynecol 170, 96102.
  • 49
    Limonta P, Dondi D, Moretti RM, Maggi R & Motta M (1992) Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 75, 207212.
  • 50
    Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E & Motta M (1994) Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 54, 40914095.
  • 51
    Montagnani Marelli M, Moretti RM, Dondi D, Limonta P & Motta M (1997) Effects of LHRH agonists on the growth of human prostatic tumor cells: ‘in vitro’ and ‘in vivo’ studies. Arch Ital Urol Androl 69, 257263.
  • 52
    Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M & Schally AV (1997) Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer 33, 11411148.
  • 53
    Kraus S, Levy G, Hanoch T, Naor Z & Seger R (2004) Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Res 64, 57365744.
  • 54
    Enomoto M, Seong JY, Kawashima S & Park MK (2004) Proliferation of TSU-Pr1, a human prostatic carcinoma cell line is stimulated by gonadotropin-releasing hormone. Life Sci 74, 31413152.
  • 55
    Enomoto M, Endo D, Kawashima S & Park MK (2004) Human type II GnRH receptor mediates effects of GnRH on cell proliferation. Zool Sci 21, 763770.
  • 56
    Miller WR, Scott WN, Morris R, Fraser HM & Sharpe RM (1985) Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313, 231233.
  • 57
    Gunthert AR, Grundker C, Olota A, Lasche J, Eicke N & Emons G (2005) Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen. Eur J Endocrinol 153, 613625.
  • 58
    Sharoni Y, Bosin E, Miinster A, Levy J & Schally AV (1989) Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 86, 16481651.
  • 59
    Raga F, Casan EM, Wen Y, Huang HY, Bonilla-Musoles F & Polan ML (1999) Independent regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-3 in human endometrial stromal cells by gonadotropin-releasing hormone: implications in early human implantation. J Clin Endocrinol Metab 84, 636642.
  • 60
    Chou CS, Zhu H, Shalev E, MacCalman CD & Leung PC (2002) The effects of gonadotropin-releasing hormone (GnRH) I and GnRH II on the urokinase-type plasminogen activator/plasminogen activator inhibitor system in human extravillous cytotrophoblasts in vitro. J Clin Endocrinol Metab 87, 55945603.
  • 61
    Moretti RM, Montagnani Marelli M, Van Groeninghen JC & Limonta P (2002) Locally expressed LHRH receptors mediate the oncostatic and antimetastatic activity of LHRH agonists on melanoma cells. J Clin Endocrinol Metab 87, 37913797.
  • 62
    Moretti RM, Monagnani Marelli M, van Groeninghen JC, Motta M & Limonta P (2003) Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression. Endocr Relat Cancer 10, 161167.
  • 63
    Hierowski MT, Wettler O & Schally AV (1984) Plasminogen activator and nuclear androgen receptor in rat prostate tumors after treatment with D-Trp-6-LH-RH. Biomed Pharmacother 38, 297303.
  • 64
    Dondi D, Festuccia C, Piccolella M, Bologna M & Motta M (2006) GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system. Oncol Rep 15, 393400.
  • 65
    Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN & Leung HY (2005) Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. J Pathol 206, 205213.
  • 66
    Yates C, Wells A & Turner T (2005) Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline. Br J Cancer 92, 366375.
  • 67
    Enomoto M, Utsumi M & Park MK (2006) Gonadotropin-releasing hormone induces actin cytoskeleton remodeling and affects cell migration in a cell-type-specific manner in TSU-Pr1 and DU145 cells. Endocrinology 147, 530542.
  • 68
    von Alten J, Fister S, Schulz H, Viereck V, Frosch KH, Emons G & Grundker C (2006) GnRH analogs reduce invasiveness of human breast cancer cells. Breast Cancer Res Treat 100, 1321.
  • 69
    Chen A, Ganor Y, Rahimipour S, Ben-Aroya N, Koch Y & Levite M (2002) The neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs. Nat Med 8, 14211426.
  • 70
    Parborell F, Irusta G, Rodriguez Celin A & Tesone M (2008) Regulation of ovarian angiogenesis and apoptosis by GnRH-I analogs. Mol Reprod Dev 75, 623631.
  • 71
    Taylor PD, Hillier SG & Fraser HM (2004) Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary. J Endocrinol 183, 117.
  • 72
    Di Lieto A, De Falco M, Pollio F, Mansueto G, Salvatore G, Somma P, Ciociola F, De Rosa G & Staibano S (2005) Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig 12, 123128.
  • 73
    Kraus S, Naor Z & Seger R (2006) Gonadotropin-releasing hormone in apoptosis of prostate cancer cells. Cancer Lett 234, 109123.
  • 74
    Imai A, Horibe S, Takagi A & Tamaya T (1997) Gi protein activation of gonadotropin-releasing hormone-mediated protein dephosphorylation in human endometrial carcinoma. Am J Obstet Gynecol 176, 371376.
  • 75
    Kraus S, Benard O, Naor Z & Seger R (2003) c-Src is activated by the epidermal growth factor receptor in a pathway that mediates JNK and ERK activation by gonadotropin-releasing hormone in COS7 cells. J Biol Chem 278, 3261832630.
  • 76
    Kimura A, Ohmichi M, Kurachi H, Ikegami H, Hayakawa J, Tasaka K, Kanda Y, Nishio Y, Jikihara H, Matsuura N et al. (1999) Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line. Cancer Res 59, 51335142.
  • 77
    Kim KY, Choi KC, Park SH, Chou CS, Auersperg N & Leung PC (2004) Type II gonadotropin-releasing hormone stimulates p38 mitogen-activated protein kinase and apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 89, 30203026.
  • 78
    Shah BH, Farshori MP, Jambusaria A & Catt KJ (2003) Roles of Src and epidermal growth factor receptor transactivation in transient and sustained ERK1/2 responses to gonadotropin-releasing hormone receptor activation. J Biol Chem 278, 1911819126.
  • 79
    Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179185.
  • 80
    Kao S, Jaiswal RK, Kolch W & Landreth GE (2001) Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells. J Biol Chem 276, 1816918177.
  • 81
    Pouyssegur J, Volmat V & Lenormand P (2002) Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol 64, 755763.
  • 82
    Chakraborti S, Mandal M, Das S, Mandal A & Chakraborti T (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253, 269285.
  • 83
    Shah BH, Soh JW & Catt KJ (2003) Dependence of gonadotropin-releasing hormone-induced neuronal MAPK signaling on epidermal growth factor receptor transactivation. J Biol Chem 278, 28662875.
  • 84
    Roelle S, Grosse R, Aigner A, Krell HW, Czubayko F & Gudermann T (2003) Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone. J Biol Chem 278, 4730747318.
  • 85
    Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, Motta M & Limonta P (1996) Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 81, 39303937.
  • 86
    Grundker C, Volker P & Emons G (2001) Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology 142, 23692380.
  • 87
    Eicke N, Gunthert AR, Emons G & Grundker C (2006) GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells. Int J Oncol 29, 12231229.
  • 88
    Lamharzi N, Halmos G, Jungwirth A & Schally AV (1998) Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int J Oncol 13, 429435.
  • 89
    Montagnani Marelli M, Moretti RM, Mai S, Procacci P & Limonta P (2007) Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. Int J Oncol 30, 261271.
  • 90
    Marelli MM, Moretti RM, Dondi D, Motta M & Limonta P (1999) Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology 140, 329334.
  • 91
    Lamharzi N, Schally AV & Koppan M (1998) Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regul Pept 77, 185192.
  • 92
    Bifulco G, Miele C, Pellicano M, Trencia A, Ferraioli M, Paturzo F, Tommaselli GA, Beguinot F & Nappi C (2004) Molecular mechanisms involved in GnRH analogue-related apoptosis for uterine leiomyomas. Mol Hum Reprod 10, 4348.
  • 93
    Shah BH, Neithardt A, Chu DB, Shah FB & Catt KJ (2006) Role of EGF receptor transactivation in phosphoinositide 3-kinase-dependent activation of MAP kinase by GPCRs. J Cell Physiol 206, 4757.
  • 94
    Grundker C, Schulz K, Gunthert AR & Emons G (2000) Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 85, 38153820.
  • 95
    Sakamoto Y, Harada T, Horie S, Iba Y, Taniguchi F, Yoshida S, Iwabe T & Terakawa N (2003) Tumor necrosis factor-alpha-induced interleukin-8 (IL-8) expression in endometriotic stromal cells, probably through nuclear factor-kappa B activation: gonadotropin-releasing hormone agonist treatment reduced IL-8 expression. J Clin Endocrinol Metab 88, 730735.
  • 96
    Choi JR, Park DW, Choi DS & Min CK (2006) Role of integrin, FAK (focal adhesion kinase) and ERK (extracellular signal regulated kinase) on the suppressed cell proliferation of endometrial cancer cells by GnRH (gonadotropin-releasing hormone). Korean J Fertil Steril 33, 115123.
  • 97
    Chegini N & Kornberg L (2003) Gonadotropin releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma. J Soc Gynecol Investig 10, 2126.
  • 98
    Maudsley S, Davidson L, Pawson AJ, Freestone SH, Lopez de Maturana R, Thomson AA & Millar RP (2006) Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5. Neuroendocrinology 84, 285300.
  • 99
    Kaiser UB, Conn PM & Chin WW (1997) Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocr Rev 18, 4670.
  • 100
    Haisenleder DJ, Cox ME, Parsons SJ & Marshall JC (1998) Gonadotropin-releasing hormone pulses are required to maintain activation of mitogen-activated protein kinase: role in stimulation of gonadotrope gene expression. Endocrinology 139, 31043111.
  • 101
    Krsmanovic LZ, Mores N, Navarro CE, Arora KK & Catt KJ (2003) An agonist-induced switch in G protein coupling of the gonadotropin-releasing hormone receptor regulates pulsatile neuropeptide secretion. Proc Natl Acad Sci USA 100, 29692974.
  • 102
    Loumaye E & Catt KJ (1982) Homologous regulation of gonadotropin-releasing hormone receptors in cultured pituitary cells. Science 215, 983985.
  • 103
    Liu F, Usui I, Evans LG, Austin DA, Mellon PL, Olefsky JM & Webster NJ (2002) Involvement of both G(q/11) and G(s) proteins in gonadotropin-releasing hormone receptor-mediated signaling in L beta T2 cells. J Biol Chem 277, 3209932108.
  • 104
    Krsmanovic LZ, Mores N, Navarro CE, Tomic M & Catt KJ (2001) Regulation of Ca2+-sensitive adenylyl cyclase in gonadotropin-releasing hormone neurons. Mol Endocrinol 15, 429440.
  • 105
    Grosse R, Schmid A, Schoneberg T, Herrlich A, Muhn P, Schultz G & Gudermann T (2000) Gonadotropin-releasing hormone receptor initiates multiple signaling pathways by exclusively coupling to G(q/11) proteins. J Biol Chem 275, 91939200.
  • 106
    Guo CH, Janovick JA, Kuphal D & Conn PM (1995) Transient transfection of GGH3-1′ cells [GH3 cells stably transfected with the gonadotropin-releasing hormone (GnRH) receptor complementary deoxyribonucleic acid] with the carboxyl-terminal of beta-adrenergic receptor kinase 1 blocks prolactin release: evidence for a role of the G protein beta gamma-subunit complex in GnRH signal transduction. Endocrinology 136, 30313036.
  • 107
    Clapham DE & Neer EJ (1993) New roles for G-protein beta gamma-dimers in transmembrane signalling. Nature 365, 403406.
  • 108
    Federman AD, Conklin BR, Schrader KA, Reed RR & Bourne HR (1992) Hormonal stimulation of adenylyl cyclase through Gi-protein beta gamma subunits. Nature 356, 159161.
  • 109
    Tang WJ & Gilman AG (1991) Type-specific regulation of adenylyl cyclase by G protein beta gamma subunits. Science 254, 15001503.
  • 110
    Kaiser UB, Jakubowiak A, Steinberger A & Chin WW (1993) Regulation of rat pituitary gonadotropin-releasing hormone receptor mRNA levels in vivo and in vitro. Endocrinology 133, 931934.
  • 111
    Kang SK, Cheng KW, Nathwani PS, Choi KC & Leung PC (2000) Autocrine role of gonadotropin-releasing hormone and its receptor in ovarian cancer cell growth. Endocrine 13, 297304.
  • 112
    Kaiser UB, Sabbagh E, Katzenellenbogen RA, Conn PM & Chin WW (1995) A mechanism for the differential regulation of gonadotropin subunit gene expression by gonadotropin-releasing hormone. Proc Natl Acad Sci USA 92, 1228012284.
  • 113
    McArdle CA, Gorospe WC, Huckle WR & Conn PM (1987) Homologous down-regulation of gonadotropin-releasing hormone receptors and desensitization of gonadotropes: lack of dependence on protein kinase C. Mol Endocrinol 1, 420429.
  • 114
    Lu ZL, Gallagher R, Sellar R, Coetsee M & Millar RP (2005) Mutations remote from the human gonadotropin-releasing hormone (GnRH) receptor-binding sites specifically increase binding affinity for GnRH II but not GnRH I: evidence for ligand-selective, receptor-active conformations. J Biol Chem 280, 2979629803.
  • 115
    Lu ZL, Coetsee M, White CD & Millar RP (2007) Structural determinants for ligand–receptor conformational selection in a peptide G protein-coupled receptor. J Biol Chem 282, 1792117929.
  • 116
    Shimizu M & Bedecarrats GY (2006) Identification of a novel pituitary-specific chicken gonadotropin-releasing hormone receptor and its splice variants. Biol Reprod 75, 800808.
  • 117
    Zhou W & Sealfon SC (1994) Structure of the mouse gonadotropin-releasing hormone receptor gene: variant transcripts generated by alternative processing. DNA Cell Biol 13, 605614.
  • 118
    Kottler ML, Bergametti F, Carre MC, Morice S, Decoret E, Lagarde JP, Starzec A & Counis R (1999) Tissue-specific pattern of variant transcripts of the human gonadotropin-releasing hormone receptor gene. Eur J Endocrinol 140, 561569.
  • 119
    Grosse R, Schoneberg T, Schultz G & Gudermann T (1997) Inhibition of gonadotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor. Mol Endocrinol 11, 13051318.
  • 120
    Bahk JY, Hyun JS, Lee H, Kim MO, Cho GJ, Lee BH & Choi WS (1998) Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells. Urol Res 26, 259264.
  • 121
    Chatzistamou I, Schally AV, Varga JL, Groot K, Busto R, Armatis P & Halmos G (2001) Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anticancer Drugs 12, 761768.
  • 122
    Osborne CK, Hobbs K & Trent JM (1987) Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat 9, 111121.
  • 123
    Dickson RB, Bates SE, McManaway ME & Lippman ME (1986) Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res 46, 17071713.
  • 124
    Xie D, Miller CW, O’Kelly J, Nakachi K, Sakashita A, Said JW, Gornbein J & Koeffler HP (2001) Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 276, 1418714194.
  • 125
    Yao JJ, Liu Y, Lacorazza HD, Soslow RA, Scandura JM, Nimer SD & Hedvat CV (2007) Tumor promoting properties of the ETS protein MEF in ovarian cancer. Oncogene 26, 40324037.
  • 126
    Hongo A, Kuramoto H, Nakamura Y, Hasegawa K, Nakamura K, Kodama J & Hiramatsu Y (2003) Antitumor effects of a soluble insulin-like growth factor I receptor in human ovarian cancer cells: advantage of recombinant protein administration in vivo. Cancer Res 63, 78347839.
  • 127
    Webber MM, Bello D & Quader S (1997) Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 2. Tumorigenic cell lines. Prostate 30, 5864.
  • 128
    Sobel RE & Sadar MD (2005) Cell lines used in prostate cancer research: a compendium of old and new lines – part 1. J Urol 173, 342359.
  • 129
    Kyo S, Nakamura M, Kiyono T, Maida Y, Kanaya T, Tanaka M, Yatabe N & Inoue M (2003) Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol 163, 22592269.
  • 130
    Tanaka R, Saito T, Ashihara K, Nishimura M, Mizumoto H & Kudo R (2003) Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells. Gynecol Oncol 90, 297304.
  • 131
    Sillem M, Prifti S, Koumouridis A & Runnebaum B (1999) Invasiveness corresponds to differentiation rather than to proteinase secretion in endometrial cancer cell lines. Eur J Gynaecol Oncol 20, 367370.
  • 132
    Stone KR, Mickey DD, Wunderli H, Mickey GH & Paulson DF (1978) Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21, 274281.
  • 133
    Honjo Y, Nangia-Makker P, Inohara H & Raz A (2001) Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 7, 661668.
  • 134
    Mukhopadhyay R, Theriault RL & Price JE (1999) Increased levels of alpha6 integrins are associated with the metastatic phenotype of human breast cancer cells. Clin Exp Metastasis 17, 325332.
  • 135
    Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME et al. (1992) Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150, 534544.
  • 136
    Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR & Ozols RF (1983) Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43, 53795389.
  • 137
    Maeda T, Tashiro H, Katabuchi H, Begum M, Ohtake H, Kiyono T & Okamura H (2005) Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability. Br J Cancer 93, 116123.
  • 138
    Millar R, Lowe S, Conklin D, Pawson A, Maudsley S, Troskie B, Ott T, Millar M, Lincoln G, Sellar R et al. (2001) A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci USA 98, 96369641.
  • 139
    Illing N, Troskie BE, Nahorniak CS, Hapgood JP, Peter RE & Millar RP (1999) Two gonadotropin-releasing hormone receptor subtypes with distinct ligand selectivity and differential distribution in brain and pituitary in the goldfish (Carassius auratus). Proc Natl Acad Sci USA 96, 25262531.
  • 140
    Neill JD, Duck LW, Sellers JC & Musgrove LC (2001) A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates. Biochem Biophys Res Commun 282, 10121018.
  • 141
    Neill JD (2002) GnRH and GnRH receptor genes in the human genome. Endocrinology 143, 737743.
  • 142
    Eicke N, Gunthert AR, Viereck V, Siebold D, Behe M, Becker T, Emons G & Grundker C (2005) GnRH-II receptor-like antigenicity in human placenta and in cancers of the human reproductive organs. Eur J Endocrinol 153, 605612.
  • 143
    Morgan K, Conklin D, Pawson AJ, Sellar R, Ott TR & Millar RP (2003) A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. Endocrinology 144, 423436.
  • 144
    Pawson AJ, Faccenda E, Maudsley S, Lu ZL, Naor Z & Millar RP (2007) Mammalian type I GnRH receptors undergo slow, constitutive, agonist-independent internalization. Endocrinology 149, 14151422.
  • 145
    Finch AR, Green L, Hislop JN, Kelly E & McArdle CA (2004) Signaling and antiproliferative effects of type I and II gonadotropin-releasing hormone receptors in breast cancer cells. J Clin Endocrinol Metab 89, 18231832.
  • 146
    Okada Y, Murota-Kawano A, Kakar SS & Winters SJ (2003) Evidence that gonadotropin-releasing hormone (GnRH) II stimulates luteinizing hormone and follicle-stimulating hormone secretion from monkey pituitary cultures by activating the GnRH I receptor. Biol Reprod 69, 13561361.
  • 147
    Kauffman AS, Wills A, Millar RP & Rissman EF (2005) Evidence that the type-2 gonadotrophin-releasing hormone (GnRH) receptor mediates the behavioural effects of GnRH-II on feeding and reproduction in musk shrews. J Neuroendocrinol 17, 489497.
  • 148
    van Biljon W, Wykes S, Scherer S, Krawetz SA & Hapgood J (2002) Type II gonadotropin-releasing hormone receptor transcripts in human sperm. Biol Reprod 67, 17411749.
  • 149
    Maiti K, Oh DY, Moon JS, Acharjee S, Li JH, Bai DG, Park HS, Lee K, Lee YC, Jung NC et al. (2005) Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death. J Clin Endocrinol Metab 90, 42874298.
  • 150
    Yahalom D, Chen A, Ben-Aroya N, Rahimipour S, Kaganovsky E, Okon E, Fridkin M & Koch Y (1999) The gonadotropin-releasing hormone family of neuropeptides in the brain of human, bovine and rat: identification of a third isoform. FEBS Lett 463, 289294.